Physician profile
Jairo Brieva
NPI 1316914849
$1,575.26
in general payments reported to CMS, 2019-2025
21 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $25.14 · 2021: $50.00 · 2023: $85.90 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $193.08 | 2025 | Rexulti |
| Ethicon INC. | $188.86 | 2025 | Monarch Platform |
| Bayer Healthcare Pharmaceuticals INC. | $164.11 | 2025 | |
| Novo Nordisk INC | $121.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $116.70 | 2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Cequr Corporation | $100.01 | 2025 | Cequr Simplicity |
| Boston Scientific Corporation | $97.21 | 2019 | |
| Intuitive Surgical, INC. | $85.90 | 2023 | Da Vinci Surgical System |
| Lilly USA, LLC | $74.39 | 2025 | Zepbound, Mounjaro, Kisunla |
| Axsome Therapeutics, INC. | $61.21 | 2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $49.32 | 2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $48.81 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $41.96 | 2025 | Korlym |
| Philips North America LLC | $39.60 | 2025 | Extended Holter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $25.32 | 2025 | Sublocade |
| Edwards Lifesciences Corporation | $25.14 | 2020 | |
| Daiichi Sankyo INC. | $23.75 | 2025 | Injectafer |
| Paratek Pharmaceuticals, INC. | $23.42 | 2025 | Xhance, Nuzyra |
| Janssen Pharmaceuticals, INC | $23.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.07 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Brieva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.